Unity Biotechnology (UBX) Peer Comparison

$0.07

$-0.09 (-56.25%)

As on 08-Aug-2025 09:30EDT

Market cap

$3 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

2.6

Div. Yield

0 %

Edit

	Unity Biotechnology (UBX)	Vigil Neuroscience (VIGL)
Market cap ($ Mln)	3	376
Revenue ($ Mln)	--	0
Net Profit ($ Mln)	-27.50	-92.17
Net Margin (%)	--	-20,390.49
RoE (%)	--	-163.28
Price to Earnings	--	--
Price-To-Book	2.59	9.11

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Unity Biotechnology (UBX)	Vigil Neuroscience (VIGL)
Operating Revenue	0.00	0.45
Cost of Revenue	-0.89	0.46
Gross Profit	--	-0.45
Operating Expenses	30.19	96.75
Operating Profit (EBIT)	-29.96	-96.75
Other Income	0.00	0.00
Profit before Tax	-27.50	-92.17
Provision for Tax	-0.58	0.00
Profit after Tax (Net Income)	-27.50	-92.17
Minority Interest	0.00	0.00
Consolidated Profit	0.00	0.00

Liabilities ($ Mln)

	Unity Biotechnology (UBX)	Vigil Neuroscience (VIGL)
Shareholder's Funds	-0.21	41.26
Minority Interest	0.00	0.00
Non-Current Liabilities	21.49	11.33
Current Liabilities	9.07	34.11
Total Liabilities	37.66	117.69

Assets ($ Mln)

	Unity Biotechnology (UBX)	Vigil Neuroscience (VIGL)
Non-Current Assets	12.70	16.41
Current Assets	17.65	70.29
Total Assets	37.66	117.69
Total Debt*	18.68	12.44
Net Current Assets	8.58	36.18

Cashflow ($ Mln)

	Unity Biotechnology (UBX)	Vigil Neuroscience (VIGL)
Cash From Operating Activities	-20.87	-51.22
Cash Flow from Investing Activities	8.57	8.76
Cash from Financing Activities	0.08	29.49
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Unity Biotechnology (UBX)	Vigil Neuroscience (VIGL)
ROCE (%)	-60.85	-78.49
ROE (%)	-148.97	-163.28
ROA (%)	-51.89	-76.79
EBIT Margin (%)	--	-21,199.78
Net Margin (%)	--	-20,390.49
Cash Profit Margin (%)	--	-0.04

Growth Ratios

	Unity Biotechnology (UBX)	Vigil Neuroscience (VIGL)
Revenue Growth (%)	--	-76.63
EBIT Growth (%)	17.15	-6.39
Net Profit Growth (%)	20.93	-9.93
EPS Growth (%)	--	1.39
Book Value Growth (%)	--	-58.79

Valuation Ratios

	Unity Biotechnology (UBX)	Vigil Neuroscience (VIGL)
Price / Earnings	--	-0.84
Price / Book Value	--	0.99
Dividend Yield (%)	--	--
EV/EBITDA	-0.01	0.17
Market Cap ($ Cr)	--	--

Solvency Ratios

	Unity Biotechnology (UBX)	Vigil Neuroscience (VIGL)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	-18.68	0.05
Current Ratio	1.95	2.06
Quick Ratio	1.95	2.06
Interest Coverage	--	--

Operating Efficiency Ratios

	Unity Biotechnology (UBX)	Vigil Neuroscience (VIGL)
Debtors to sales (%)	--	123.45
Asset Turnover	0.00	0.00
Receivable days	--	--
Inventory Days	--	--
Payable days	--	1,577.51
Cash Conversion Cycle	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly